AAA
SWTX

Affinity Asset Advisors’s SpringWorks Therapeutics SWTX Stock Holding History

Affinity Asset Advisors’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-160,000
Closed -$9.03M – 68
2022
Q1 		$9.03M Buy
+160,000
New +$9.16M 1.44% 12

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Affinity Asset Advisors's SWTX Position: Q4 2024 in Review

Affinity Asset Advisors sold out of SpringWorks Therapeutics (SWTX) in Q4 2024, closing a stake of 147,500 shares — an estimated $4.73M sold.

Affinity Asset Advisors first reported a position in SWTX in Q1 2021 and held it in 12 quarters. The position peaked at $18.5M in Q4 2021. 216 funds tracked by Wall St. Rank hold SWTX as of Q4 2024.

  • Affinity Asset Advisors reported no remaining SpringWorks Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Affinity Asset Advisors sold 147,500 SpringWorks Therapeutics shares in Q4 2024, an estimated $4.73M.
  • Affinity Asset Advisors first reported a position in SpringWorks Therapeutics in Q1 2021 and held it in 12 quarters.
  • Affinity Asset Advisors's SpringWorks Therapeutics position peaked at $18.5M in Q4 2021.
  • 216 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2024.

Based on Affinity Asset Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.